Page 116 - Human Use News Today

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) said that a 30-microgram booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 Vaccine has been recommended for conditional

This article outlines the role of microbiome-based products and the impact it can have on gut health.

(RTTNews) - Novavax Inc. (NVAX) said on Monday that the European Commission has approved the expanded conditional marketing authorization of Nuvax...

By Stephen Nakrosis Pfizer Inc. and BioNTech SE said Monday the European Medicines Agencys Committee for Medicinal Products for Human Use, or CHMP, recommended a conditional marketing... | September 12, 2022

Investegate announcements from BioNTech SE, Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union

Nuvaxovid™ is now authorized in the EU for use in adults aged 18 and older as a booster regardless of previous vaccine historyGAITHERSBURG, Md., S...

CHMP recommendation based on favorable data from Omicron-adapted vaccines The Omicron BA.4/BA.5 bivalent COVID-19 booster vaccine combines 15-ug of mRNA encoding the wild-type spike protein

Dublin, Sept. 09, 2022 (GLOBE NEWSWIRE) -- The "Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Enzyme Type,...

The Regulation on Pharmaceutical Establishments and Products in Pharmaceutical Establishments, drafted by the Turkish Pharmaceuticals and Medical Devices Agency, was published in Official Gazette dated 15 June 2022 and numbered 31867 and entered into force on the same date.

Teva announced today that the European Commission has granted marketing authorization for RANIVISIO, a biosimilar ranibizumab, for the treatment of…